Wanbury Limited (BOM:524212)

Market Cap	7.83B -10.5%
Revenue (ttm)	6.53B +3.3%
Net Income	558.87M +30.0%
EPS	16.34 +29.9%
Shares Out	34.94M
PE Ratio	13.71
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,727
Open	226.75
Previous Close	225.35
Day's Range	222.85 - 229.25
52-Week Range	162.00 - 360.00
Beta	0.16
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Wanbury

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API por...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 1,200
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524212

Financial Performance

In fiscal year 2026, Wanbury's revenue was 6.50 billion, an increase of 8.35% compared to the previous year's 6.00 billion. Earnings were 661.35 million, an increase of 116.62%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 27, 2026

Data Sources Report a data error